RecruitingHealthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
Eligible age
18–55 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
Sponsor: AstraZeneca
You may qualify if…
- ✓ Healthy participants with suitable veins for cannulation or repeated venipuncture.
- ✓ All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
- ✓ Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.
- ✓ Females of non-childbearing potential must be confirmed at screening visit as postmenopausal or have documentation of irreversible surgical sterilization.
- ✓ Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.
- ✓ Have a body mass index between 18.5 and 30 kg/m2 inclusive and weigh at least 50 kg.
You may not qualify if…
- ✕ History of any clinically important disease or disorder.
- ✕ History of acute pancreatitis.
- ✕ History or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- ✕ Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
- ✕ Any clinically important illness, medical/surgical procedure, or trauma.
- ✕ Participants who have previously received elecoglipron within the last 3 months.
Where it's recruiting
California
Glendale
Maryland
Brooklyn
Source: ClinicalTrials.gov · NCT07723833 · last updated 2026-08-20